Achieving potent autologous neutralizing antibody responses against tier 2 HIV-1 viruses by strategic selection of envelope immunogens

Journal of Immunology

Volumn 196, Issue 7, 2016, Pages 3064-3078

  Hessell, Ann J ^a   Malherbe, Delphine C ^a   Pissani, Franco ^a,b   McBurney, Sean ^a   Krebs, Shelly J ^c   Gomes, Michelle ^a   Pandey, Shilpi ^a   Sutton, William F ^a   Burwitz, Benjamin J ^a,c   Gray, Matthew ^d   Robins, Harlan ^e   Park, Byung S ^a   Sacha, Jonah B ^a,c   La Branche, Celia C ^f   Fuller, Deborah H ^g   Montefiori, David C ^f   Stamatatos, Leonidas ^e   Sather, D Noah ^d   Haigwood, Nancy L ^a,h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Military HIV Research Program   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Seattle BioMed   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f DUKE UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING COMPETITION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENVELOPE GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; DISEASE MODEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOID TISSUE; METABOLISM; SERODIAGNOSIS; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; LYMPHOID TISSUE; MACACA MULATTA; NEUTRALIZATION TESTS; T-LYMPHOCYTE SUBSETS; VACCINATION;

EID: 84962605521     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500527     Document Type: Article

References (76)

1. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. De Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
2. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009. Effective, lowtiter antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954.
3. Mascola, J. R., M. G. Lewis, G. Stiegler, D. Harris, T. C. Van Cott, D. Hayes, M. K. Louder, C. R. Brown, C. V. Sapan, S. S. Frankel, et al. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
4. Moldt, B., E. G. Rakasz, N. Schultz, P. Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard, and D. R. Burton. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109:18921-18925.
5. Parren, P. W., P. A. Marx, A. J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J. P. Moore, and D. R. Burton. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347.
6. Ng, C. T., J. P. Jaworski, P. Jayaraman, W. F. Sutton, P. Delio, L. Kuller, D. Anderson, G. Landucci, B. A. Richardson, D. R. Burton, et al. 2010. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16:1117-1119.
7. Nishimura, Y., T. Igarashi, N. L. Haigwood, R. Sadjadpour, O. K. Donau, C. Buckler, R. J. Plishka, A. Buckler-White, and M. A. Martin. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 100:15131-15136.
8. Barouch, D. H., J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H. W. Chang, K. Shekhar, S. Gupta, et al. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224-228.
9. Shingai, M., Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak, Jr., J. D. Lifson, et al. 2013. Antibodymediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503:277-280.
10. Klein, F., A. Halper-Stromberg, J. A. Horwitz, H. Gruell, J. F. Scheid, S. Bournazos, H. Mouquet, L. A. Spatz, R. Diskin, A. Abadir, et al. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492:118-122.
11. Halper-Stromberg, A., C. L. Lu, F. Klein, J. A. Horwitz, S. Bournazos, L. Nogueira, T. R. Eisenreich, C. Liu, A. Gazumyan, U. Schaefer, et al. 2014. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-999.
12. Doria-Rose, N. A., G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M. Mahalanabis, M. T. Hensel, S. McLaughlin, P. F. Edmonson, D. Montefiori, et al. 2005. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79:11214-11224.
13. Chakrabarti, B. K., Y. Feng, S. K. Sharma, K. McKee, G. B. Karlsson Hedestam, C. C. Labranche, D. C. Montefiori, J. R. Mascola, and R. T. Wyatt. 2013. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J. Virol. 87:13239-13251.
14. Dey, A. K., K. B. David, M. Lu, and J. P. Moore. 2009. Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385:275-281.
15. Sundling, C., M. N. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S. S. Rao, K. Loré, J. R. Mascola, R. T. Wyatt, I. Douagi, and G. B. Karlsson Hedestam. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003-2017.
16. Blish, C. A., D. N. Sather, G. Sellhorn, L. Stamatatos, Y. Sun, I. Srivastava, S. W. Barnett, B. Cleveland, J. Overbaugh, and S. L. Hu. 2010. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 84:2573-2584.
17. Guenaga, J., P. Dosenovic, G. Ofek, D. Baker, W. R. Schief, P. D. Kwong, G. B. Karlsson Hedestam, and R. T. Wyatt. 2011. Heterologous epitope-scaffold prime: boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 6:e16074.
18. Bomsel, M., D. Tudor, A. S. Drillet, A. Alfsen, Y. Ganor, M. G. Roger, N. Mouz, M. Amacker, A. Chalifour, L. Diomede, et al. 2011. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-280.
19. Seaman, M. S., L. Xu, K. Beaudry, K. L. Martin, M. H. Beddall, A. Miura, A. Sambor, B. K. Chakrabarti, Y. Huang, R. Bailer, et al. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79:2956-2963.
20. Du, S. X., L. Xu, W. Zhang, S. Tang, R. I. Boenig, H. Chen, E. B. Mariano, M. B. Zwick, P. W. Parren, D. R. Burton, et al. 2011. A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One 6:e20927.
21. Barouch, D. H., K. E. Stephenson, E. N. Borducchi, K. Smith, K. Stanley, A. G. McNally, J. Liu, P. Abbink, L. F. Maxfield, M. S. Seaman, et al. 2013. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155:531-539.
22. Malherbe, D. C., F. Pissani, D. N. Sather, B. Guo, S. Pandey, W. F. Sutton, A. B. Stuart, H. Robins, B. Park, S. J. Krebs, et al. 2014. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J. Virol. 88:12949-12967.
23. Li, J., A. Valentin, V. Kulkarni, M. Rosati, R. K. Beach, C. Alicea, D. Hannaman, S. G. Reed, B. K. Felber, and G. N. Pavlakis. 2013. HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 31:3747-3755.
24. Jalah, R., V. Kulkarni, V. Patel, M. Rosati, C. Alicea, J. Bear, L. Yu, Y. Guan, X. Shen, G. D. Tomaras, et al. 2014. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. PLoS One 9:e91550.
25. Patel, V., R. Jalah, V. Kulkarni, A. Valentin, M. Rosati, C. Alicea, A. Von Gegerfelt, W. Huang, Y. Guan, B. F. Keele, et al. 2013. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc. Natl. Acad. Sci. USA 110:2975-2980.
26. Asmal, M., C. Luedemann, C. L. Lavine, L. V. Mach, H. Balachandran, C. Brinkley, T. N. Denny, M. G. Lewis, H. Anderson, R. Pal, et al. 2015. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475:37-45.
27. Sather, D. N., S. Carbonetti, D. C. Malherbe, F. Pissani, A. B. Stuart, A. J. Hessell, M. D. Gray, I. Mikell, S. A. Kalams, N. L. Haigwood, and L. Stamatatos. 2014. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J. Virol. 88:12968-12981.
28. Malherbe, D. C., N. A. Doria-Rose, L. Misher, T. Beckett, W. B. Puryear, J. T. Schuman, Z. Kraft, J. O'Malley, M. Mori, I. Srivastava, et al. 2011. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 85:5262-5274.
29. Srivastava, I. K., K. Van Dorsten, L. Vojtech, S. W. Barnett, and L. Stamatatos. 2003. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77:2310-2320.
30. Sellhorn, G., Z. Caldwell, C. Mineart, and L. Stamatatos. 2009. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudostable transient transfection. Vaccine 28:430-436.
31. Blay, W. M., T. Kasprzyk, L. Misher, B. A. Richardson, and N. L. Haigwood. 2007. Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J. Virol. 81:13037-13049.
32. Zolla-Pazner, S., A. C. De Camp, T. Cardozo, N. Karasavvas, R. Gottardo, C. Williams, D. E. Morris, G. Tomaras, M. Rao, E. Billings, et al. 2013. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 8:e53629.
33. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
34. Montefiori, D. C. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485:395-405.
35. Sarzotti-Kelsoe, M., X. Daniell, C. A. Todd, M. Bilska, A. Martelli, C. La Branche, L. G. Perez, C. Ochsenbauer, J. C. Kappes, W. Rountree, et al. 2014. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J. Immunol. Methods 409:147-160.
36. Derby, N. R., Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80:8745-8762.
37. Krebs, S. J., S. P. McBurney, D. N. Kovarik, C. D. Waddell, J. P. Jaworski, W. F. Sutton, M. M. Gomes, M. Trovato, G. Waagmeester, S. J. Barnett, et al. 2014. Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPERspecific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA. [Published erratum appears in 2015 PLoS One. DOI: 10.1371/journal.pone.0120027]. PLoS One 9:e113463.
38. Sanders, R. W., R. Derking, A. Cupo, J. P. Julien, A. Yasmeen, N. De Val, H. J. Kim, C. Blattner, A. T. De La Peña, J. Korzun, et al. 2013. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9:e1003618.
39. Pugach, P., G. Ozorowski, A. Cupo, R. Ringe, A. Yasmeen, N. De Val, R. Derking, H. J. Kim, J. Korzun, M. Golabek, et al. 2015. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J. Virol. 89:3380-3395.
40. Xu, J. Y., M. K. Gorny, T. Palker, S. Karwowska, and S. Zolla-Pazner. 1991. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65:4832-4838.
41. Pinter, A., W. J. Honnen, S. C. Kayman, O. Trochev, and Z. Wu. 1998. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16:1803-1811.
42. Zhou, T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
43. Dey, B., K. Svehla, L. Xu, D. Wycuff, T. Zhou, G. Voss, A. Phogat, B. K. Chakrabarti, Y. Li, G. Shaw, et al. 2009. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5:e1000445.
44. Wu, X., Z. Y. Yang, Y. Li, C. M. Hogerkorp, W. R. Schief, M. S. Seaman, T. Zhou, S. D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
45. Lynch, R. M., L. Tran, M. K. Louder, S. D. Schmidt, M. Cohen, R. Dersimonian, Z. Euler, E. S. Gray, S. Abdool Karim, J. Kirchherr, et al; CHAVI 001 Clinical Team Members. 2012. The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86:7588-7595.
46. De Camp, A., P. Hraber, R. T. Bailer, M. S. Seaman, C. Ochsenbauer, J. Kappes, R. Gottardo, P. Edlefsen, S. Self, H. Tang, et al. 2014. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88:2489-2507.
47. Walker, L. M., S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, et al; Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
48. Frost, S. D., T. Wrin, D. M. Smith, S. L. Kosakovsky Pond, Y. Liu, E. Paxinos, C. Chappey, J. Galovich, J. Beauchaine, C. J. Petropoulos, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102:18514-18519.
49. Moore, P. L., N. Ranchobe, B. E. Lambson, E. S. Gray, E. Cave, M. R. Abrahams, G. Bandawe, K. Mlisana, S. S. Abdool Karim, C. Williamson, and L. Morris, CAPRISA 002 Study, NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI). 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
50. Rong, R., B. Li, R. M. Lynch, R. E. Haaland, M. K. Murphy, J. Mulenga, S. A. Allen, A. Pinter, G. M. Shaw, E. Hunter, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
51. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
52. Montefiori, D. C., C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M. S. De Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, et al. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-441.
53. Sather, D. N., J. Armann, L. K. Ching, A. Mavrantoni, G. Sellhorn, Z. Caldwell, X. Yu, B. Wood, S. Self, S. Kalams, and L. Stamatatos. 2009. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
54. Blish, C. A., O. C. Dogan, N. R. Derby, M. A. Nguyen, B. Chohan, B. A. Richardson, and J. Overbaugh. 2008. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 82:12094-12103.
55. Seaman, M. S., H. Janes, N. Hawkins, L. E. Grandpre, C. Devoy, A. Giri, R. T. Coffey, L. Harris, B. Wood, M. G. Daniels, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84:1439-1452.
56. Liao, H. X., C. Y. Tsao, S. M. Alam, M. Muldoon, N. Vandergrift, B. J. Ma, X. Lu, L. L. Sutherland, R. M. Scearce, C. Bowman, et al. 2013. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J. Virol. 87:4185-4201.
57. Bar, K. J., C. Y. Tsao, S. S. Iyer, J. M. Decker, Y. Yang, M. Bonsignori, X. Chen, K. K. Hwang, D. C. Montefiori, H. X. Liao, et al. 2012. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 8:e1002721.
58. Sanders, R. W., M. J. Van Gils, R. Derking, D. Sok, T. J. Ketas, J. A. Burger, G. Ozorowski, A. Cupo, C. Simonich, L. Goo, et al. 2015. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 349: aac4223.
59. FH). Annu. Rev. Immunol. 29:621-663.
60. Petrovas, C., T. Yamamoto, M. Y. Gerner, K. L. Boswell, K. Wloka, E. C. Smith, D. R. Ambrozak, N. G. Sandler, K. J. Timmer, X. Sun, et al. 2012. CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Invest. 122:3281-3294.
61. Fukazawa, Y., H. Park, M. J. Cameron, F. Lefebvre, R. Lum, N. Coombes, E. Mahyari, S. I. Hagen, J. Y. Bae, M. D. Reyes, III, et al. 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat. Med. 18:1673-1681.
62. + T cells express high levels of CXCR5 and IL-21 and display a CCR7 (lo) ICOS+Bcl6+ T-follicular helper (Tfh) cell phenotype. PLoS One 8:e59758.
63. Perreau, M., A. L. Savoye, E. De Crignis, J. M. Corpataux, R. Cubas, E. K. Haddad, L. De Leval, C. Graziosi, and G. Pantaleo. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210:143-156.
64. Locci, M., C. Havenar-Daughton, E. Landais, J. Wu, M. A. Kroenke, C. L. Arlehamn, L. F. Su, R. Cubas, M. M. Davis, A. Sette, et al; International AIDS Vaccine Initiative Protocol C Principal Investigators. 2013. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39:758-769.
65. Sok, D., U. Laserson, J. Laserson, Y. Liu, F. Vigneault, J. P. Julien, B. Briney, A. Ramos, K. F. Saye, K. Le, et al. 2013. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 9:e1003754.
66. Klein, F., R. Diskin, J. F. Scheid, C. Gaebler, H. Mouquet, I. S. Georgiev, M. Pancera, T. Zhou, R. B. Incesu, B. Z. Fu, et al. 2013. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153:126-138.
67. McGuire, A. T., J. A. Glenn, A. Lippy, and L. Stamatatos. 2014. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 88:2645-2657.
68. Jardine, J., J. P. Julien, S. Menis, T. Ota, O. Kalyuzhniy, A. McGuire, D. Sok, P. S. Huang, S. MacPherson, M. Jones, et al. 2013. Rational HIV immunogen design to target specific germline B cell receptors. Science 340:711-716.
69. Fiebig, E. W., D. J. Wright, B. D. Rawal, P. E. Garrett, R. T. Schumacher, L. Peddada, C. Heldebrant, R. Smith, A. Conrad, S. H. Kleinman, and M. P. Busch. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
70. Mörner, A., I. Douagi, M. N. Forsell, C. Sundling, P. Dosenovic, S. O'Dell, B. Dey, P. D. Kwong, G. Voss, R. Thorstensson, et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540-551.
71. Martinez, P., C. Sundling, S. O'Dell, J. R. Mascola, R. T. Wyatt, and G. B. Karlsson Hedestam. 2015. Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation. Sci. Rep. 5:8925.
72. Cubas, R. A., J. C. Mudd, A. L. Savoye, M. Perreau, J. Van Grevenynghe, T. Metcalf, E. Connick, A. Meditz, G. J. Freeman, G. Abesada-Terk, Jr., et al. 2013. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19:494-499.
73. Streeck, H., M. P. D'Souza, D. R. Littman, and S. Crotty. 2013. Harnessing CD4. T cell responses in HIV vaccine development. Nat. Med. 19:143-149.
74. Lindqvist, M., J. Van Lunzen, D. Z. Soghoian, B. D. Kuhl, S. Ranasinghe, G. Kranias, M. D. Flanders, S. Cutler, N. Yudanin, M. I. Muller, et al. 2012. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122:3271-3280.
75. FH cells are critical for broad antibody development in SHIVAD8 infection. Sci. Transl. Med. 7:298ra120.
76. Piantadosi, A., D. Panteleeff, C. A. Blish, J. M. Baeten, W. Jaoko, R. S. McClelland, and J. Overbaugh. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.